Navigation Links
AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use
Date:10/19/2011

NEW YORK, Oct. 19, 2011 /PRNewswire/ -- It is well known that ophthalmologists around the world often prescribe Avastin (bevacizumab) off-label for wet age-related macular degeneration (AMD) over the approved treatment Lucentis (ranibizumabintravitreal) due to cost and the belief that the two have similar efficacy.

AMD Alliance International (AMDAI) is calling for ophthalmologists to stop this practice in light of a concerning surge in eye infections over the past month in patients being treated with repackaged Avastin.(i) The US Food and Drug Administration (FDA) has issued a formal warning to health care professionals about Avastin's risk for infection(ii). The US Department of Veterans Affairs has also stopped using Avastin in wet AMD patients.(iii) The Alliance urges other healthcare providers to follow suit.    

"AMDAI always advocates that evidence-based medicine and patient safety should set as the preferred treatment protocol for wet AMD, not cost," said Narinder Sharma BSc. Hons., MBA, PGDL, CEO of AMDAI. "In this case, the approved treatment based on safety and efficacy data is Lucentis. Unfortunately, we have effectively traded patient safety for money. That is just not acceptable."

Furthermore, since Avastin is not approved for ocular use, there is no pharma covigilance program for Avastin in ocular use, therefore side effects and safety issues are not monitored or reported.

AMDAI is also strongly recommending the following actions:

  • Patients and caregivers should practice increased vigilance and informed consent:
    • Patients should ask their health care providers about and fully acknowledge all possible risks associated with Avastin.
    • Patients should work with their health care providers to gain access to approved treatments whenever possible.
  • Physicians should stop prescribing Avastin as the first-line treatment for wet AMD, as advised by the US Department of Veterans Affairs(iii), especially if Lucentis is available to their patients through insurance coverage.  
  • Manufacturers of licensed therapies, Medicare and other health insurers should work together to increase access to safe and approved treatments.  

"AMD is a debilitating disease and without treatment can lead to blindness," said Alan Cruess, MD, Chairman, Department of Ophthalmology and Visual Sciences, Dalhousie University and Chairman of AMDAI's Scientific Advisory Panel. "Patients diagnosed with AMD are going through a lot of confusion and uncertainty. They need access to safe and effective medicines and shouldn't have to worry about sacrificing safety when it comes to treatment."

AMDAI strongly encourages doctors, patients with wet AMD and their caregivers to fully understand the issue before making a treatment decision. A more detailed summary of known risks and cost issues associated with Avastin and Lucentis is available at amdalliance.org.

About AMDAI

AMD Alliance International strives to bring knowledge, help and hope to individuals and families around the world affected by AMD. Our mission is accomplished through:

  • Generating awareness and understanding of age-related macular degeneration;
  • Promoting the importance of education, early detection, knowledge of treatment and rehabilitation options; and
  • Preserving vision and improving the quality of life of individuals affected by age-related macular degeneration.  

(i) Consists of aggregate data from the following countries:


(ii) FDA Alerts Health Care Professionals of Infection Risk from Repackaged AvastinIntravitreal Injections. Available at http://www.fda.gov/Drugs/DrugSafety/ucm270296.htm

(iii) US Department of Veterans Affairs public statement.


'/>"/>
SOURCE AMDAI
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OXIS International Assumes Control and Exploitation Rights to Key L-Ergothioneine Patent Filing Representing a Major Market Opportunity
2. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):